Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of rituximab + bendamustine in relapsed or refractory follicular lymphoma after first-line rituximab-chemotherapy
2008-007650-35Phase 2Active
- Sponsor
- GOTEL
- Start
- Feb 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and bendamustine in follicular lymphoma (FL), sponsored by GOTEL. Primary endpoint: Complete response and unconfirmed complete response. Started Feb 2009; status: active.
02
Drugs
rituximabbendamustine
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2008-007650-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007650-35.